[8-K] Athira Pharma, Inc. Reports Material Event

Rhea-AI Filing Summary

Athira Pharma (ATHA)

The company notes that information under Items 2.02 and 7.01, and Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Athira also highlights its disclosure channels, including its website, investor site, and social media accounts on X (@athirapharma), LinkedIn, Instagram (@athirapharma), and Facebook.

11/06/2025 - 04:09 PM

0001620463false00016204632025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Athira Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39503	45-3368487
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

18706 North Creek Parkway, Suite 104
Bothell, WA 98011

(Address of principal executive offices, including zip code)

(425) 620-8501

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	ATHA	The Nasdaq Stock Market LLC  (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act). ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s website (www.athira.com), its investor relations website (investors.athira.com), and its news site (investors.athira.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its X account (@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), Instagram account (@athirapharma) and Facebook page (www.facebook.com/athirapharmainc), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Athira Pharma, Inc. press release dated November 6, 2025
104		Cover Page Interactive Data File (formatted as Inline XBRL)

The information furnished in this Current Report under Items 2.02 and 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Athira Pharma, Inc.
Date:	November 6, 2025	By:	/s/ Mark Litton
			Mark Litton
			President and Chief Executive Officer

FAQ

What did Athira Pharma (ATHA) announce in this 8-K?

Athira furnished an 8-K noting it issued a press release reporting financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1.

Which period do Athira Pharma's results cover?

The press release reports financial results for the quarter ended September 30, 2025.

How is the information in this 8-K treated legally?

Information under Items 2.02 and 7.01, and Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.

Where can I find Athira Pharma's official updates?

Athira uses SEC filings, press releases, conference calls, www.athira.com, investors.athira.com, and its social media channels to share material information.

What exhibit accompanies this 8-K for Athira (ATHA)?

Exhibit 99.1, which is the press release dated November 6, 2025, and Exhibit 104, the cover page Inline XBRL file.

Which social media accounts does Athira reference?

X (@athirapharma), LinkedIn (linkedin.com/company/athirapharma), Instagram (@athirapharma), and Facebook (facebook.com/athirapharmainc).